Eligibility Varies Across the 3 Sodium-glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials Among Adults With Type 2 Diabetes: Implications From Analysis of the Diabetes Collaborative Registry
Year: 2018
Type: article
Authors: Eric Wittbrodt, David Chamberlain, Suzanne Arnold, Fengming Tang, Mikhail Kosiborod
Institution: AstraZeneca (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2789542308
